Skip to content

BAUDREZ RX

Active Private limited companyfounded 2006active for 19 yearsChemin du Berger 1, 5336 AssesseKBO/BCE: BE 0885.813.896

Lifetime

19 annual accounts with figures on one time axis
peak of €227,409 in 2025
€227,409▲ 3.7%
peak of €200,178 in 2024
€189,985▼ 5.1%
peak of €382,765 in 2024
€326,399▼ 14.7%
€362,165▲ 176%
Board1 name since 2021
1 director
Documentsfilings and deeds
28-08-202628 days late
2025micro format
Dividend €246,350Equity from €382,765 to €326,399Debts from €131,141 to €362,165Cash from €109,336 to €452,620

Key points

from the 2025 annual accounts

Equity

€326,399 ▼ 14.7%
382,7652024+189,985Profit-246,350Dividend326,3992025

BAUDREZ RX paid out €246,350 in dividends. That is 130% of the 2025 profit.

Turnover

≈ €420,000 estimated

The micro format states no turnover.

Debts

€362,165 ▲ 176%
Other debts
+233,059
Taxes and wages
+15,174
Financial debts
+1,728
The rest
-18,937

Debts rose by €231,024 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Liquidity

1.62 was 3.13 in 2024

Short-term debts rose from €131,141 to €362,165.

Filings

19 annual accounts since 2007
AprilJune31 JulyOctober2010201520202025

Seven of the last ten came late. The 2024 accounts came in latest, 61 days after the end of the period.

Position in the sector

€189,985

Higher net result than 86% of companies in human health. Sector median €59,520 · 21,355 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,816 companies had the same profile as BAUDREZ RX has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,816 companies, not a prediction for BAUDREZ RX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0885813896
resigns as manager reappointed as director · Director discharge: (manager) · Gazette deed
Incorporation published on 02-01-2007 · Gazette deed
All 27 events

Comparable companies

same main activity, similar in size and age
Company
BAUDREZ RX Assesse €688,564 €227,409 47.4% -
JC GOEMINNE Namur €756,737 €210,445 74.7% -
Dr. Jo DUCHATEAU Lier €690,292 €227,419 80.5% -
DOCTEUR LEONIE DEUGOUE Remicourt €712,732 €216,255 44.2% -
DERMALAUKES Etterbeek €707,037 €217,192 54.2% -
Dr. De Clippel, gynaecologie-verloskunde Hoeilaart €731,752 €219,736 45.1% -
DOCTEUR MATUS ONCOLOGY Trooz €733,176 €218,040 40.7% -

These companies have the same main activity as BAUDREZ RX: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €690,000 and €757,000, founded between 2006 and 2008.

Official details

Source: KBO
Status
Active since 19-12-2006Normal situation
Activity
Specialist medical practiceNACE 86220
Financial year end
31 December
Peppol
Reachable since 18-12-2025
Company details

Annual accounts 2025

€688,564▲ 34.0%
Filing
Filed on 28-08-2026
Financials

Insights on BAUDREZ RX

BAUDREZ RX files the micro format. That format states no turnover. The gross margin rose from €109,548 in 2007 to €227,409 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about BAUDREZ RX

What is the company number of BAUDREZ RX?
The company number of BAUDREZ RX is 0885.813.896. The VAT number is the same number with BE in front: BE 0885.813.896.
Where is BAUDREZ RX based?
The registered office is at Chemin du Berger 1, 5336 Assesse.Company details
What does BAUDREZ RX do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of BAUDREZ RX?
BAUDREZ RX is a private limited company (BV).
When was BAUDREZ RX founded?
BAUDREZ RX was founded on 19-12-2006.
Is BAUDREZ RX still active?
Yes, BAUDREZ RX is an active enterprise in the KBO register.
What is the turnover of BAUDREZ RX?
The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €227,409 and 40 comparable companies (NACE 86220). It probably lies between €360,000 and €560,000.Financials
Is BAUDREZ RX profitable?
In financial year 2025, BAUDREZ RX made a profit of €189,985.
Where can I find the annual accounts of BAUDREZ RX?
BAUDREZ RX filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BAUDREZ RX due?
BAUDREZ RX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.